XML 16 R10.htm IDEA: XBRL DOCUMENT
v3.25.1

Nature of the Business | 3 Months Ended
--- | ---
Mar. 31, 2025
Accounting Policies [Abstract] |
Nature of the Business | 1. Nature of the Business Vor Biopharma Inc. (the “Company”) is a clinical-stage cell and genome engineering company that combines a novel patient engineering approach with targeted therapies to provide a single company solution for patients suffering from hematological malignancies. The Company’s proprietary platform leverages its expertise in hematopoietic stem cell (“HSC”) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company is headquartered in Cambridge, Massachusetts. The Company was incorporated on December 30, 2015. On May 8, 2025, the Company announced the wind-down of its clinical and manufacturing operations, which includes a plan to implement a reduction of the Company’s workforce, as the Company conducts a process to explore strategic alternatives to maximize shareholder value. Refer to Note 13, Subsequent Events, to these interim condensed consolidated financial statements for further discussion of this non-recognized subsequent event. Risks and Uncertainties The Company is subject to a number of risks common to development stage companies in the biotechnology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, dependence on key personnel, protection of proprietary technology, reliance on third party organizations, uncertainty of obtaining regulatory approval for any product candidate that it may develop, development by competitors of technological innovations, compliance with government regulations, adverse macroeconomic conditions and the need to obtain additional financing. In addition, as the Company winds down its clinical and manufacturing operations and explores strategic alternatives, it is subject to additional risks, including, without limitation, risks of unforeseen delays or other challenges in winding down its operations, unintended consequences and unanticipated costs associated with the workforce reduction, such as the loss of institutional knowledge and expertise, attrition beyond the intended number of employees and decreased morale among remaining employees, and the uncertainty of consummating a strategic transaction, any of which may result in further cost-saving initiatives in the future or the business ceasing to continue as a going concern. The Company anticipates that it will continue to incur significant operating losses as it pursues strategic alternatives aimed at maximizing shareholder value. Liquidity and Capital Resources As of March 31, 2025, the Company had $60.0 million of cash, cash equivalents and marketable securities and an accumulated deficit of $489.5 million. The Company has also announced that it is winding down its clinical and manufacturing operations and exploring strategic alternatives. The Company anticipates that it will continue to incur significant operating losses for the foreseeable future as it explores strategic alternatives. As a result, the Company’s continued operations are dependent on its ability to consummate a strategic transaction and/or raise additional funding. Based on its current capital resources, combined with the need to enter into a strategic transaction and/or raise additional funding and the uncertainty regarding consummating such a transaction and/or the availability of such additional funding, management has concluded that there is substantial doubt regarding the Company’s ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt regarding the Company’s ability to continue as a going concern include obtaining additional funding through equity or debt offerings and/or pursuant to collaboration or licensing arrangements. However, additional funding may not be available on terms acceptable to the Company or at all, and the Company may instead engage in, among other alternatives, a potential sale or licensing of its assets, an in-license arrangement, sale of the company, business combination, merger or other strategic transaction. There can be no assurance that the Company will be able to consummate any such strategic alternative on acceptable terms or at all. If, for any reason, the Company utilizes its capital resources more quickly than anticipated or is unable to obtain additional funding on a timely basis and/or complete a strategic transaction, the Company may be required to further revise its business plan and strategy or cease operations. This may limit the strategic options available to the Company. As a result, the Company’s business, financial condition, and results of operations could be materially affected. The accompanying condensed consolidated financial statements do not include any adjustments to the carrying amounts and classification of assets and liabilities that may be necessary if the Company were unable to continue as a going concern.

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContent Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details
Name: | us-gaap_NatureOfOperations
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration